GET DAILY SIGNALSNovavax (NVAX) Stock: -20% Monthly Pullback After October Spike, Yet +28% Over the Quarter
Key Takeaways
- Novavax (NVAX) shares fell roughly 20% over the past 30 days, from a closing level near $12.75 in early October to $10.20, largely retracing a sharp early-October rally.
- The early-October surge was driven by a suspected pneumonic plague case in Russia and heavy short-covering, rather than a change in Novavax's underlying business.
- Despite the pullback, Novavax's third-quarter 2026 results beat Wall Street estimates and the company raised its full-year revenue guidance.
- Novavax received a $125 million milestone payment from Sanofi in late October after the partner initiated a Phase 3 combination-vaccine trial in Europe.
- Over the trailing quarter, NVAX is still up roughly 28%, supported by multi-market approvals of its updated COVID-19 vaccine and continued partnership progress.
- For additional detail on valuation and fundamentals, explore Novavax's Price Targets, Earnings, and Forecast pages.
- Investors tracking automated trading strategies can review Trending AI Robots for relevant bot activity across the market.
Novavax (NVAX) Company Background and Strategy
Novavax, Inc. is a Gaithersburg, Maryland-based biotechnology company focused on the discovery, development, and commercialization of vaccines for serious infectious diseases. Its flagship product is Nuvaxovid, a protein-based COVID-19 vaccine built on the company's proprietary Matrix-M adjuvant technology, and the company also supplies Matrix-M for partners' products, including the R21 malaria vaccine.
Rather than maintaining a large independent commercial organization, Novavax has shifted toward a partnership-driven, capital-light licensing model. The centerpiece is a broad agreement with Sanofi covering development and commercialization of COVID-19 and combination vaccines, supplemented by arrangements with other partners. I think investors follow the stock closely for milestones, royalties, and progress toward the company's stated goal of reaching profitability by 2028. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
NVAX Stock Price Action: Last 30 Days Versus the Quarter
Over the past 30 days, NVAX declined approximately 20%, moving from a closing price near $12.75 in early October to $10.20. That pullback came immediately after the stock touched its 52-week high of about $13.38 intraday on October 5, and it reflects a mean reversion from an unusually sharp, sentiment-driven spike.
The longer three-month picture is different. From a level near $7.95 in mid-August, the stock has risen roughly 28%, supported by a series of constructive developments, including updated vaccine approvals, partnership milestones, and improving financial results. In short, the 30-day decline represents a partial unwind of October's spike rather than a breakdown of the broader uptrend.
What Sparked the Recent 30-Day Move in NVAX
The dominant catalyst was the early-October rally and its subsequent unwind. On October 5, Novavax shares jumped about 20% after reports of a suspected pneumonic plague case in Russia renewed interest in vaccine and infectious-disease names. Novavax's elevated short interest — roughly 30% of its float at the time — amplified the move through short-covering, while Moderna and other peers also gained.
That rally proved short-lived. As authorities reported no additional confirmed infections and outbreak fears faded, profit-taking set in, and the stock gave back much of its advance over the following weeks. Sentiment was further tempered by Citi's reiteration of a Sell rating on October 15 and the news that activist investor Shah Capital ended its campaign against the company.
Fundamentally, however, the news flow was constructive. On October 29, Novavax confirmed receipt of a $125 million milestone payment from Sanofi following initiation of a Phase 3 combination-vaccine trial in Europe. Then, on November 5, the company reported third-quarter revenue of $68 million, beating consensus estimates, and a narrower-than-expected net loss of $31 million, while raising its full-year adjusted revenue guidance to a midpoint of $400 million. The stock's decline in recent weeks therefore reflects position unwinding and shifting sentiment more than deterioration in the company's financial trajectory. From what I see, I’m watching this closely for any follow-through on the Sanofi partnership.
Drivers Behind the Broader Quarterly Advance
The trailing quarter's roughly 28% advance was anchored by steady execution of the company's partnership strategy. In late August, Novavax announced that its updated XFG-adapted Nuvaxovid had received approvals in the United States, European Union, and Japan for the 2026-2027 vaccination season, supporting royalty income from partner-led sales.
Second-quarter results, reported in early August, also showed a narrower-than-expected loss and revenue above forecasts, while management reiterated its framework for reaching profitability by 2028 under the Sanofi agreement. Those developments, combined with the October milestone payment and the raised full-year outlook, underpinned the broader multi-month move even as the stock pulled back from its October peak.
Key Factors to Monitor Going Forward
Looking ahead, the key variables for Novavax are the pace of partner-driven milestones and royalties under the Sanofi agreement, including a potential additional payment tied to a U.S. launch of Sanofi's combination flu-COVID vaccine. Investors should also monitor updates on the 2026-2027 vaccination season, demand for Nuvaxovid and Matrix-M supply sales, and management's progress toward the profitability target it has set for 2028.
Analyst expectations remain divided: several brokerages rate the stock Buy or better with targets well above recent levels, while others maintain Sell ratings, with a median target near $11. Because Novavax remains a pre-profit, milestone-dependent biotechnology company, results can remain sensitive to clinical-trial news, regulatory decisions, and shifts in infectious-disease sentiment, making headline risk an ongoing consideration for investors. One thing that stands out is how sensitive the shares remain to external sentiment shifts.
Integrating Tickeron AI Tools Into My Research
In my own analysis of names like NVAX, I often turn to Tickeron’s AI Trading Bots to see how systematic strategies are handling volatility and momentum across biotech. These tools help me compare different approaches without relying solely on manual charting. The platform’s marketplace of automated bots gives a clear view of trending strategies that align with the current market environment, which I find useful when evaluating position sizing or timing around milestone-driven events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NVAX in +11.35% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NVAX advanced for three days, in 192 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on NVAX as a result. In 61 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVAX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 21 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
NVAX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NVAX broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NVAX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.324) is normal, around the industry mean (3.498). P/E Ratio (-7.046) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.759) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology
Advertisement